EGRP News Flash - December 16, 2011
Reissuance of Small Grants Program for Cancer Epidemiology
The National Cancer Institute's (NCI) Epidemiology and Genomics Research Program (EGRP) announces the reissuance of a Funding Opportunity Announcement (FOA) under the NIH Small Research Grant (R03) funding mechanism to support research on cancer etiology and epidemiology. This FOA provides support for pilot projects, testing of new techniques, secondary analyses of existing data, development and validation of measurement methods, linkage of genetic polymorphisms with other variables related to cancer risk, and development of innovative projects for more comprehensive research in cancer etiology and epidemiology.
Given the limits of the scientific scope appropriate for the mechanism of this FOA, specific topics of interest may include, but are not limited to, the following four key areas of research:
- Methods and Technologies focuses on methods to address epidemiologic data collection, study design and analysis, and to modify technological approaches developed in the context of other research endeavors for use as biomarkers and methods to understand cancer susceptibility.
- Modifiable Risk Factors focuses on factors that may be modifiable, such as diet and nutrition, alcohol, physical activity and energy balance, tobacco, infectious diseases, physical and chemical agents, and medical exposures including medications and treatments.
- Host Susceptibility Factors focuses on personal susceptibility factors such as genetic, epigenetic, immunological and hormonal biological pathways, and social, cultural, and race/ethnic factors.
- Clinical and Translational Epidemiology focuses on clinical factors that influence development of cancer among persons with underlying diseases and conditions; the progression, recurrence, and mortality from cancer; and new primary cancers.
In addition, investigators are encouraged to propose epidemiologic studies using new approaches, such as those involving use of circulating DNA, exfoliated cells, haplotype analysis, immunoassays, in silico assays, mass spectrometry, microsatellite assays, and proteomic arrays.
Applicants are encouraged to submit applications to study cancer sites that have previously been traditionally understudied. These include cancers of the esophagus, endometrium, liver, hematopoietic system (especially multiple myeloma), pancreas, testes, and brain.
Investigators are encouraged to validate measurements in body fluids and tissues of exogenous exposures associated with development of cancer using biospecimen repositories from some of the largest epidemiological cohorts supported by EGRP.
A project period of up to two years may be requested with a budget for direct costs of up to $50,000 per year. The 2012 application due dates are March 19, July 17, and November 19. Applications are due by 5:00 PM local time of the applicant organization. This announcement expires on November 19, 2014.
The NCI research and scientific contact is EGRP's Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch.
Access the NIH Guide for Grants and Contracts for details: